Page last updated: 2024-08-24

triazoles and buparlisib

triazoles has been researched along with buparlisib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT	1
Huang, P; Liu, X; Wu, H; Zhang, F	1
Huang, P; Li, Q; Liu, X; Tong, D; Wu, H; Zhang, F	1

Trials

1 trial(s) available for triazoles and buparlisib

Article	Year
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-20, Volume: 32, Issue:12 Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Letrozole; Middle Aged; Morpholines; Multimodal Imaging; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles	2014

Article

Year

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-20, Volume: 32, Issue:12

Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Letrozole; Middle Aged; Morpholines; Multimodal Imaging; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles

2014

Other Studies

2 other study(ies) available for triazoles and buparlisib

Article	Year
JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2019, Volume: 48, Issue:1 Topics: Aminopyridines; Apoptosis; Azepines; Carcinoma, Adenoid Cystic; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Gene Expression; Humans; Molecular Targeted Therapy; Morpholines; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Salivary Gland Neoplasms; Signal Transduction; Transcription Factors; Triazoles; Tumor Cells, Cultured	2019
EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1. Journal of cellular biochemistry, 2018, Volume: 119, Issue:10 Topics: Aminopyridines; Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Azepines; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Gene Knockdown Techniques; Humans; Mice; Morpholines; Mouth Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays	2018

Article

Year

JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2019, Volume: 48, Issue:1

Topics: Aminopyridines; Apoptosis; Azepines; Carcinoma, Adenoid Cystic; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Gene Expression; Humans; Molecular Targeted Therapy; Morpholines; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Salivary Gland Neoplasms; Signal Transduction; Transcription Factors; Triazoles; Tumor Cells, Cultured

2019

EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.

Journal of cellular biochemistry, 2018, Volume: 119, Issue:10

Topics: Aminopyridines; Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Azepines; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Gene Knockdown Techniques; Humans; Mice; Morpholines; Mouth Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays

2018